Evidence map›Paper›PMID 29589479›Full record

ArticleDrug delivery2018

Magnetically assisted intraperitoneal drug delivery for cancer chemotherapy.

Milad Shamsi, Amir Sedaghatkish, Morteza Dejam, Mohsen Saghafian, Mehdi Mohammadi, Amir Sanati-Nezhad

Abstract readComparative StudyValidation Study
In one paragraph

Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Magnetic particle targeting for diagnosis and therapy of lung cancers.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Milad Shamsia Department of Mechanical and Manufacturing Engineering, BioMEMS and Bioinspired Microfluidic Laboratory , University of Calgary , Calgary , AB , Canada.
Amir Sedaghatkishc Department of Mechanical Engineering , Isfahan University of Technology , Isfahan , Iran.
Morteza Dejamd Department of Petroleum Engineering, College of Engineering and Applied Science , University of Wyoming , Laramie , WY , USA.
Mohsen Saghafianc Department of Mechanical Engineering , Isfahan University of Technology , Isfahan , Iran.
Mehdi Mohammadia Department of Mechanical and Manufacturing Engineering, BioMEMS and Bioinspired Microfluidic Laboratory , University of Calgary , Calgary , AB , Canada.
Amir Sanati-Nezhada Department of Mechanical and Manufacturing Engineering, BioMEMS and Bioinspired Microfluidic Laboratory , University of Calgary , Calgary , AB , Canada.ORCID http://orcid.org/0000-0002-2309-2388

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intraperitoneal (IP) chemotherapy has revived hopes during the past few years for the management of peritoneal disseminations of digestive and gynecological cancers. Nevertheless, a poor drug penetration is one key drawback of IP chemotherapy since peritoneal neoplasms are notoriously resistant to drug penetration. Recent preclinical studies have focused on targeting the aberrant tumor microenvironment to improve intratumoral drug transport. However, tumor stroma targeting therapies have limited therapeutic windows and show variable outcomes across different cohort of patients. Therefore, the development of new strategies for improving the efficacy of IP chemotherapy is a certain need. In this work, we propose a new magnetically assisted strategy to elevate drug penetration into peritoneal tumor nodules and improve IP chemotherapy. A computational model was developed to assess the feasibility and predictability of the proposed active drug delivery method. The key tumor pathophysiology, including a spatially heterogeneous construct of leaky vasculature, nonfunctional lymphatics, and dense extracellular matrix (ECM), was reconstructed in silico. The transport of intraperitoneally injected magnetic nanoparticles (MNPs) inside tumors was simulated and compared with the transport of free cytotoxic agents. Our results on magnetically assisted delivery showed an order of magnitude increase in the final intratumoral concentration of drug-coated MNPs with respect to free cytotoxic agents. The intermediate MNPs with the radius range of 200-300 nm yield optimal magnetic drug targeting (MDT) performance in 5-10 mm tumors while the MDT performance remains essentially the same over a large particle radius range of 100-500 nm for a 1 mm radius small tumor. The success of MDT in larger tumors (5-10 mm in radius) was found to be markedly dependent on the choice of magnet strength and tumor-magnet distance while these two parameters were less of a concern in small tumors. We also validated in silico results against experimental results related to tumor interstitial hypertension, conventional IP chemoperfusion, and magnetically actuated movement of MNPs in excised tissue.

Indexed as

Absorption, PhysiologicalDrug Delivery SystemsMagnetic PhenomenaModels, BiologicalAlgorithmsAnimalsAntineoplastic AgentsComputational BiologyComputer SimulationExpert SystemsExtracellular FluidFeasibility StudiesHumansInjections, IntralesionalInjections, IntraperitonealMagnetite NanoparticlesAntineoplastic AgentsMagnetite Nanoparticlescomputational and mathematical tumor modelingdesmoplasiadrug penetration depthinterstitial hypertensionIntraperitoneal drug deliverymagnetic drug targetingtumor microenvironment

Identifiers

PMID29589479
PMCPMC7011950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.